SING (Study of Insulin & Glyburide) Study
Women with gestational diabetes between 24 and 34 weeks gestational age who are candidates for insulin therapy are eligible for this study.
The purpose of this clinical trial is to compare the effect of the oral hypoglycemic agent glyburide to conventional subcutaneous insulin therapy on neonatal body composition using non-invasive measurements and maternal glycemic control in women with gestational diabetes.
Gestational diabetes is glucose intolerance that is first recognized during pregnancy and affects approximately 4% of pregnancies in the United States. The goal for treatment in women with gestational diabetes is normal blood sugars and generally is achieved with diet and/or subcutaneous insulin administered 1-4 times daily. An equivalent oral alternative to standard insulin therapy may be a preferable treatment for many women secondary to overall patient compliance, convenience, and satisfaction.
If you are interested in or have any questions regarding the above study, please call: